Michael Kiselow
Corneal and Contact Management · Brooklyn, NYNPI 1881673184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.0% of the total. Reporting peaked in 2022 at $667 and has fallen 91.7% since, to $55 in 2025.
Across 32 payments — averaging $88.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$737
- Bausch & Lomb, A Division Of Bausch Health US, LLC$586
- Glaukos Corporation$294
- Oyster Point Pharma, Inc.$207
- Sight Sciences, Inc.$192
- Oculus, Inc.$156
- plus $661 from 7 others
What the payments were for
- Food & beverage$2,834100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 6 | $737 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $586 |
| Glaukos Corporation | 2 | $294 |
| Oyster Point Pharma, Inc. | 2 | $207 |
| Sight Sciences, Inc. | 2 | $192 |
| Oculus, Inc. | 1 | $156 |
| AbbVie(2 entities) | 2 | $144 |
| Shire North American Group Inc | 1 | $127 |
| Sun Pharmaceutical Industries Inc. | 1 | $118 |
| Aerie Pharmaceuticals, Inc. | 1 | $107 |
| Johnson & Johnson Vision Care, Inc. | 4 | $106 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $38 |
| Alcon | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$375
- MIEBO$366
- BIOTRUE$267
- XIIDRA$249
- OCULUS Keratograph 5M$156
- TearCare SmartLid$146
- TEARCARE(TM) (2.2) SYSTEM KIT$146
- BEPREVE$125
- ALREX$125
- ULTRA$124
- BIOTRUE ONE DAY$124
- VUITY$123
- TYRVAYA$123
- VYZULTA$121
- LOTEMAX$121
- CEQUA$118
- KXL System$106
- Photrexa$106
How this compares
$2,834 in reported general payments places this provider in the 70th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $15,427 |
| XiidraLifitegrast | 13 | $8,535 |
| LumiganBimatoprost | 14 | $5,252 |
| Brimonidine Tartrate | 19 | $3,102 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $2,681 |
| Azelastine Hcl | 149 | $2,117 |
| Latanoprost | 230 | $1,274 |
| Ciprofloxacin Hcl | 54 | $412 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $144 | $23,36152 claims |
| Bausch & Lomb Americas Inc.Xiidra | $737 | $8,53513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in Brooklyn
- Jeffrey CooperBrooklyn$52K
- Stanislav IlyushaBrooklyn$3K
- Jacqueline ChangBrooklyn$388
- Lindsey ChanBrooklyn$152
- Michele LaganaHoneoye Falls$248K
- Avani DaveBuffalo$122K
- Kevin RosinNew York$59K
- Kevork NiksarliNew York$27K
- Richard MalaraBaldwinsville$8K
- David BraunSyracuse$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.